If you follow the venture flow in orthopedics, you already know the era of the "me-too" implant is dead. Pure implant plays aren't landing Series A checks. In 2026, capital is aggressively consolidating around three core thesis buckets: enabling tech that slashes OR time, biologics that preserve native joints, and smart implants that turn traditional devices into data-generating engines.
Underneath all three lies a singular forcing function: the ASC explosion. Growing at 20–30% annually, ASCs don't care about shiny marketing brochures. They care about two metrics: Can you shave 10 minutes off a case? and Can you eliminate three instrument trays from sterilization?
That is the new currency.
Here is a breakdown of what’s actually moving the needle across the market right now.
1/ Handheld & Navigation: The Small, Modular Revolution
Hospitals are tired of $2M robotic consoles sitting idle while burning through a seven-year depreciation clock. The capital equipment model is shifting rapidly toward small, modular, handheld navigation with pay-per-click models that fit ASC economics.
THINK Surgical (TMINI): Hitting 5,000 procedures is a milestone, but the commercial power move is it...
